Drug approval: Selpercatinib and pralsetinib - RET-altered non-small cell lung cancer

xlomafota13 shared this article with you from Inoreader Drug approval: Selpercatinib and pralsetinib - RET-altered non-small cell lung cancer Via Association française pour l'étude du cancer Bull Cancer. 2021 May 19:S0007-4551(21)00172-7. doi: 10.1016/j.bulcan.2021.04.003. Online ahead of print. NO ABSTRACT PMID:34023064 | DOI:10.1016/j.bulcan.2021.04.003 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.